Olopatadine Eye Drops (Pataday, Patanol): 0.1% vs 0.2% vs 0.7%, How to Use, Side Effects and US Cost

Olopatadine eye drops treat itchy eyes caused by allergy to pollen, ragweed, grass, animal hair and dander. Olopatadine was a prescription eye drop in the US for 23 years (Patanol was approved in December 1996 and the last prescription strengths switched in 2020), sold as Patanol (0.1%), Pataday (0.2%) and Pazeo (0.7%). All three are now sold over the counter under the Pataday name, and store brand generics of each strength sit next to them on pharmacy shelves. The names changed in a way that confuses people: the bottle now called Pataday Once Daily Relief is not the same strength as Pataday Extra Strength.

This guide sets out what each strength is, the label directions, how to use the drops with contact lenses, the side effect rates from the prescribing labels, age limits, pregnancy, how olopatadine compares with ketotifen and cromolyn, when an allergy drop is the wrong choice for a red eye, and what a bottle costs US pharmacies. Every number comes from DailyMed labels, Drugs@FDA records, FDA approval documents, PubMed abstracts and the CMS NADAC price survey, all opened on 5 November 2026 (sources at the end of this page).

Olopatadine eye drops at a glance

Item	Olopatadine 0.1%	Olopatadine 0.2%	Olopatadine 0.7%
Former US prescription name	Patanol	Pataday	Pazeo
Current US OTC name	Pataday Twice Daily Relief	Pataday Once Daily Relief	Pataday Once Daily Relief Extra Strength
Drug Facts use	Temporarily relieves itchy and red eyes due to pollen, ragweed, grass, animal hair and dander	Temporarily relieves itchy eyes due to pollen, ragweed, grass, animal hair and dander	Temporarily relieves itchy eyes due to pollen, ragweed, grass, animal hair and dander
Directions	1 drop in the affected eye(s) twice daily, every 6 to 8 hours	1 drop in the affected eye(s) once daily	1 drop in the affected eye(s) once daily
Labeled age	2 years and older	2 years and older	2 years and older
Preservative	Benzalkonium chloride 0.01%	Benzalkonium chloride 0.01%	Benzalkonium chloride 0.015%
Bottle (Alcon)	5 mL	2.5 mL	2.5 mL
US OTC approval	14 February 2020	14 February 2020	13 July 2020

What olopatadine is and how it works

The olopatadine 0.1% prescribing label describes the drug as "a relatively selective H1-receptor antagonist and inhibitor of histamine release from the mast cell." In plain terms it does two things. It blocks histamine, the chemical that makes allergic eyes itch, and it reduces the release of more histamine from mast cells in the lining of the eye. The 0.2% label adds that decreased chemotaxis and inhibition of eosinophil activation have also been shown.

The label also says olopatadine "is devoid of effects on alpha-adrenergic, dopamine and muscarinic type 1 and 2 receptors."

The percentages on the box refer to olopatadine itself. The salt in the bottle is olopatadine hydrochloride, so the labels also give a slightly higher hydrochloride figure: 0.111% for the 0.1% product, 0.222% for 0.2% and 0.776% for 0.7%. That is why some trial papers call the 0.7% strength "olopatadine 0.77%."

The three strengths and their old and new names

Alcon holds the US applications for all three strengths, and the brand names were reshuffled when the drops moved to over the counter sale. The Drugs@FDA application records (openFDA) and the current Drug Facts labels on DailyMed line up like this:

Strength	FDA application	First approved (prescription)	Prescription name	OTC name today
0.1%	NDA 020688	18 December 1996	Patanol	Pataday Twice Daily Relief
0.2%	NDA 021545	22 December 2004	Pataday	Pataday Once Daily Relief
0.7%	NDA 206276	30 January 2015	Pazeo	Pataday Once Daily Relief Extra Strength

So "Patanol" and "Pazeo" are now historical names in the US. If an older prescription or website says Pataday, it most likely means the 0.2% strength, which today is Pataday Once Daily Relief. The cartons of the 0.1% and 0.2% products call themselves "Original Prescription Strength"; the 0.7% carton says "Extra Strength."

When olopatadine went over the counter

On 14 February 2020 the FDA announced that it had approved Pataday Twice Daily Relief (0.1%) and Pataday Once Daily Relief (0.2%) for nonprescription use through a prescription to OTC switch. The FDA statement said the products "will be marketed in the U.S. as nonprescription drugs and will no longer be available as prescription drugs." The openFDA record shows both as efficacy supplements approved that day (NDA 020688 supplement 32 and NDA 021545 supplement 22).

The 0.7% strength followed. The FDA approval letter for NDA 206276 supplement 5, signed 13 July 2020, says the supplement "provides for the full prescription to over-the-counter switch of olopatadine hydrochloride 0.7% ophthalmic solution," under the name Pataday Once Daily Relief (Extra Strength).

Generic copies followed the brand to the shelf. DailyMed lists OTC olopatadine 0.1% and 0.2% Drug Facts labels from makers such as Dr. Reddy's, Gland Pharma, Glenmark, and Somerset, and store brands from CVS, Walgreens, Target and Walmart. Dr. Reddy's announced on 14 January 2026 the US launch of an OTC olopatadine 0.7% generic in a 2.5 mL bottle.

Prescription labels for olopatadine eye drops still sit on DailyMed (for example two Alembic labels from 2019), and those older labels are where the side effect rates in this guide come from, because Drug Facts labels do not list rates.

What olopatadine eye drops are for

The old prescription labels describe the uses as "the treatment of the signs and symptoms of allergic conjunctivitis" (0.1%) and "the treatment of ocular itching associated with allergic conjunctivitis" (0.2% and 0.7%). The OTC Drug Facts wording is narrower and is aimed at self care: itchy eyes due to pollen, ragweed, grass, animal hair and dander. The 0.1% product also claims relief of red eyes; the 0.2% and 0.7% products claim itch relief only.

Allergic conjunctivitis is inflammation of the clear lining of the eye and inner eyelids triggered by an allergen. Itch is the symptom these drops are built to treat. They are not a treatment for infection, dry eye, a scratch on the eye or irritation from contact lenses (the Drug Facts label says "do not use to treat contact lens related irritation").

How to use olopatadine eye drops

The current Drug Facts directions are:

• 0.1% (twice daily): adults and children 2 years and older, 1 drop in the affected eye(s) twice daily, every 6 to 8 hours, no more than twice per day.
• 0.2% (once daily): 1 drop in the affected eye(s) once daily, no more than once per day.
• 0.7% (once daily, extra strength): 1 drop in the affected eye(s) once daily; do not use more than 1 drop in each eye per day.

All three labels add: if you use other eye products, wait at least 5 minutes between each product; replace the cap after each use; do not touch the tip of the container to any surface; do not use if the solution changes color or becomes cloudy; and for children under 2 years, consult a doctor.

A practical method: wash your hands, tilt your head back, pull the lower lid down to make a small pocket, look up and let one drop fall into the pocket without the tip touching the eye or lashes. Close the eye for a moment. A second drop in the same eye adds nothing on these labels; the dose is one drop.

Storage on the labels is 4 to 25 C (39 to 77 F) for the 0.1% product and 2 to 25 C (36 to 77 F) for the 0.2% and 0.7% products.

Contact lenses and benzalkonium chloride

All three OTC labels say the same thing: remove contact lenses before use, wait at least 10 minutes before reinserting them, and do not wear a contact lens if your eye is red. The reason is the preservative. The prescription labels explain that benzalkonium chloride "may be absorbed by soft contact lenses."

The older labels did not agree on the wait. The 0.1% prescription label said to wait at least ten minutes; the 2015 Pazeo label said at least five minutes; the 0.2% prescription label said ten minutes in its warnings section but, in its counseling section, that lenses "may be reinserted following administration." The current OTC wording for every strength is 10 minutes, so use that.

A red eye in a contact lens wearer is a different problem from an itchy allergic eye. Take the lenses out and get it checked rather than reaching for an allergy drop.

0.1% vs 0.2% vs 0.7%: which strength

Question	0.1%	0.2%	0.7%
Drops per day	2 (6 to 8 hours apart)	1	1
Claims redness relief on the OTC label	Yes	No	No
Label trial evidence at 24 hours	Not dosed for 24 hours	Effective in studies up to 12 weeks, once a day	Better than 0.2% on itch at 24 hours in the allergen challenge studies
Bottle and NADAC cost (generic)	5 mL, $6.20	2.5 mL, $7.45	2.5 mL, $9.31

For most people the choice comes down to convenience and how long the itch lasts. The 0.1% drop is the twice a day option. The 0.2% and 0.7% drops are once a day. In the label trials the 0.7% advantage over 0.2% showed up at 24 hours, not at the onset test, so the extra strength matters most if itch returns late in the day.

What the 0.7% trials showed

The Pazeo label rests on two conjunctival allergen challenge studies. In this design, people with known eye allergy have the allergen put into the eye after a drop, and itch is scored from 0 (none) to 4 (incapacitating). The label says a one unit difference from vehicle "is considered a clinically meaningful change."

Study 1, 3 minutes after challenge	Olopatadine 0.7% (N=66)	Olopatadine 0.2% (N=68)	Vehicle (N=68)
Onset of action	0.36	0.39	1.90
16 hours after the drop	0.70	0.87	2.20
24 hours after the drop	0.93	1.41	2.54

According to the label, 0.7% was statistically better than vehicle at 30 to 34 minutes, 16 hours and 24 hours, and better than 0.2% at 24 hours, "but not at 30-34 minutes." In Study 2 (98, 99 and 49 patients) the 24 hour scores at 3 minutes were 1.01 on 0.7%, 1.33 on 0.2% and 2.30 on vehicle.

The published trials agree. Torkildsen 2015 (202 patients) found 0.77% superior to 0.2% at 24 hours for ocular itching, conjunctival redness and total redness. McLaurin 2015 (345 subjects, also testing 0.1%) found 0.77% superior to both 0.2% and 0.1% at 24 hours, with differences in mean itch of 0.3 to 0.5 points. A pooled analysis of the two studies (448 patients, McLaurin 2017) found 17.25% more itching responders at 24 hours with 0.77% than with 0.2%, and 43.17% more than with vehicle.

Read these with their limits: allergen challenge studies use a controlled dose of allergen in a clinic, not a week of pollen season, and the 24 hour advantage over 0.2% was a fraction of a point on a 4 point scale.

Olopatadine eye drops side effects

Drug Facts labels do not give side effect rates, so the figures below come from the prescription labels for each strength. These are adverse reactions reported in the trials, and each label notes that some "were similar to the underlying disease being studied." The three strengths were tested in different trials, so the rates are not head to head.

Strength (label)	Most common	Less common
0.1% (Alembic prescription label, revised 12/2018)	Headache, 7%	Under 5%: asthenia, blurred vision, burning or stinging, cold syndrome, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid edema, nausea, pharyngitis, pruritus, rhinitis, sinusitis, taste perversion
0.2% (Alembic prescription label, 2019)	Symptoms similar to cold syndrome and pharyngitis, about 10%	5% or less. Eye: blurred vision, burning or stinging, conjunctivitis, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid edema, pain, ocular pruritus. Other: asthenia, back pain, flu syndrome, headache, increased cough, infection, nausea, rhinitis, sinusitis, taste perversion
0.7% (Pazeo label, January 2015)	2% to 5% in either group of a 6 week trial (330 on Pazeo, 169 on vehicle): blurred vision, dry eye, superficial punctate keratitis, dysgeusia, abnormal sensation in eye	None listed separately

Dysgeusia and "taste perversion" both mean an altered sense of taste.

The 0.1% prescription label lists no contraindication other than "known hypersensitivity to olopatadine hydrochloride, USP or any components." The 0.2% prescription label lists "None." The OTC labels say do not use "if you are sensitive to any ingredient in this product."

When to stop using olopatadine

All three Drug Facts labels say to stop use and ask a doctor if you experience:

• eye pain
• changes in vision
• increased redness of the eye
• itching that worsens or lasts for more than 72 hours

The 72 hour rule is the useful one. An allergy drop should make a difference within days. If it has not, the problem may not be allergy, or it may need a prescription treatment. Keep the bottle out of reach of children; if the solution is swallowed, the label says to get medical help or contact a Poison Control Center right away.

Children and age limits

Every current OTC olopatadine label is for adults and children 2 years of age and older, with "children under 2 years of age: consult a doctor." The 2015 Pazeo label said safety and effectiveness "have been established in pediatric patients two years of age and older." The 2019 prescription 0.2% label said safety and effectiveness below 2 years have not been established.

The older 0.1% prescription label was stricter: "Safety and effectiveness in pediatric patients below the age of 3 years have not been established." The current OTC 0.1% product (Pataday Twice Daily Relief) is labeled from age 2. For a toddler, ask a pediatrician or pharmacist first.

Older adults: the labels say "No overall differences in safety or effectiveness have been observed between elderly and younger patients."

Pregnancy and breastfeeding

There are no adequate and well controlled studies of olopatadine eye drops in pregnant women. The 0.1% prescription label says the drug "should be used in pregnant women only if the potential benefit to the mother justifies the potential risk to the embryo or fetus." The Pazeo label says it "should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus."

The animal findings were at oral doses far above eye use. The Pazeo label describes embryofetal toxicity in rats "at levels 1,080 to 14,400 times the maximum recommended human ophthalmic dose" and no toxicity in rat offspring at exposures 45 to 150 times that at the human dose.

For breastfeeding, olopatadine has been found in the milk of nursing rats after oral dosing. The labels say it is not known whether eye use could produce detectable amounts in human milk, and that "caution should be exercised" in a nursing mother. The current OTC Drug Facts labels we read contain no pregnancy or breastfeeding statement, so the older labels are the guide. If you are pregnant or breastfeeding, ask your doctor or pharmacist before using any eye drop.

How much olopatadine reaches the blood

Very little. In two studies totaling 24 healthy volunteers given olopatadine 0.15% in both eyes every 12 hours for 2 weeks, plasma levels were "generally below the quantitation limit of the assay (<0.5 ng/mL)," and quantifiable samples ranged from 0.5 to 1.3 ng/mL. About 60% to 70% of the dose was recovered unchanged in urine. The Pazeo label gives a steady-state human exposure (AUC over 12 hours) of 9.7 ng·h/mL at the recommended eye dose.

Drowsiness is not among the adverse reactions listed on any of the three prescription labels.

Olopatadine vs ketotifen (Zaditor, Alaway)

Ketotifen is the other common US over the counter allergy eye drop, sold as Zaditor, Alaway and store brands. Both drugs are antihistamines with mast cell effects. The labels differ in the details:

Item	Olopatadine 0.1% / 0.2% / 0.7%	Ketotifen 0.025% (Zaditor)
Status in the US	Over the counter	Over the counter
Directions	Twice daily (0.1%) or once daily (0.2%, 0.7%)	1 drop twice daily, every 8 to 12 hours, no more than twice per day
Labeled age	2 years and older	3 years and older
Preservative	Benzalkonium chloride 0.01% or 0.015%	Benzalkonium chloride 0.01%
Contact lens wait	10 minutes	10 minutes
Bottle and NADAC cost	Generic $6.20 to $9.31	Generic 5 mL $6.47; Zaditor 5 mL $10.25

Head to head trials are small. Patel 2018 randomized 120 patients to olopatadine 0.1% or ketotifen 0.025%. Olopatadine reduced itching, tearing, redness and total scores more by day 4, and adverse reactions were reported in 10% on olopatadine and 18% on ketotifen.

Not every study agrees. Mortemousque 2014 compared preservative free ketotifen with preserved olopatadine 0.1% in 75 adults with seasonal allergy and found no statistically significant difference in the main symptom score at day 28 (P=0.67), with a trend toward better tolerability on preservative free ketotifen at day 7 (P=0.054). A 2023 meta-analysis of 7 randomized trials (Li) found olopatadine lowered redness more (mean difference 0.77 points) but had no significant effect on itching, tearing or papillae compared with ketotifen. A 2017 meta-analysis (Kam) judged olopatadine comparable with ketotifen and epinastine, and inferior to alcaftadine on itch (pooled mean difference 0.39).

In practice: once a day dosing and the age 2 label favor olopatadine 0.2% or 0.7%. Ketotifen is a twice daily alternative for adults and children 3 and older, at about the same NADAC cost as generic olopatadine 0.1% ($6.47 vs $6.20 per 5 mL) and less than the once daily strengths.

Olopatadine vs cromolyn eye drops

Cromolyn sodium 4% eye drops are prescription only in the US, and their label is not for ordinary hay fever eyes. The Sandoz cromolyn label lists one indication: "the treatment of vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis." Seasonal allergic conjunctivitis is not on that label.

Item	Olopatadine	Cromolyn sodium 4% (US)
How it works	Antihistamine plus mast cell effect	Mast cell stabilizer; "no intrinsic vasoconstrictor, antihistaminic or anti-inflammatory activity"
Dose	1 drop once or twice daily	1 or 2 drops in each eye 4 to 6 times a day at regular intervals
Onset	Lower itch than vehicle at the onset test, 30 to 34 minutes after the drop (Pazeo label)	Response "usually evident within a few days, but longer treatment for up to six weeks is sometimes required"
Age	2 years and older	Not established below 4 years
Contact lenses	Remove; wait 10 minutes	"Do not wear contact lenses during treatment"
Most frequent side effect	Headache or cold-like symptoms (see above)	Transient ocular stinging or burning on instillation
NADAC cost	Generic $6.20 to $9.31 per bottle	10 mL $5.91

Because cromolyn works by prevention and needs regular dosing several times a day, it suits a different patient from someone who wants quick relief from a pollen day. Do not switch a child's vernal conjunctivitis treatment to an OTC drop without the prescriber.

When an allergy eye drop is the wrong choice

Olopatadine is not a treatment for bacterial or viral pink eye. The OTC labels target itch due to pollen, ragweed, grass, animal hair and dander. Thick yellow or green discharge, eyelids stuck together in the morning, eye pain, light sensitivity, a change in vision, or a red eye after an injury are not on any of these labels and need an examination.

Our guide to antibiotic eye drops covers how bacterial, viral and allergic pink eye differ and when antibiotics help. Antibiotic drops such as ofloxacin, moxifloxacin and tobramycin are prescription medicines in the US and do not relieve allergic itch. Steroid combinations such as Tobradex carry eye pressure, cataract and herpes infection warnings that make them a poor choice for self treatment of an itchy eye.

Other red flags: a red, painful eye in a contact lens wearer; a newborn with red or sticky eyes; and symptoms in one eye only that keep coming back.

Other allergy eye drops in the same group

Olopatadine is one of several dual action antihistamine drops. The 2017 Kam meta-analysis found that against placebo, olopatadine lowered ocular itch by a pooled mean difference of 1.33 points and redness by 0.92 points; it was inferior to alcaftadine on itch and comparable with epinastine and ketotifen. Our guide to prescription eye drops maps the other eye drop classes, including which allergy drops still need a prescription in the US.

Generic olopatadine and store brands

A generic or store brand olopatadine has the same active ingredient and strength as the Pataday product it copies. The inactive ingredients can differ slightly. The Alcon Pataday 0.2% bottle lists benzalkonium chloride 0.01%, dibasic sodium phosphate, edetate disodium, povidone, sodium chloride and pH adjusters; the 0.7% bottle uses a different base with benzalkonium chloride 0.015%, boric acid, hydroxypropyl gamma cyclodextrin, hypromellose, mannitol, polyethylene glycol 400 and povidone. Read the strength on the box: the store brand packs are labeled by percentage and by "twice daily" or "once daily," and the 0.2% and 0.7% packs look alike.

What olopatadine eye drops cost in the US

NADAC is the CMS survey of what US retail pharmacies pay to buy a drug. It is not the shelf price, which is higher. The latest week in the 2026 file was 4 November 2026.

Product (NADAC description)	NADAC per mL	Bottle	Per bottle
Olopatadine HCl 0.1% eye drop (generic)	$1.23939	5 mL	$6.20
Pataday Twice Daily 0.1% (brand)	$2.48194	5 mL	$12.41
Olopatadine HCl 0.2% eye drop (generic)	$2.98115	2.5 mL	$7.45
Pataday Once Daily 0.2% (brand)	$5.93969	2.5 mL	$14.85
Olopatadine HCl 0.7% eye drops (generic)	$3.72267	2.5 mL	$9.31
Pataday Once Daily 0.7% (brand)	$6.20656	2.5 mL	$15.52
Ketotifen 0.025% (generic)	$1.29449	5 mL	$6.47
Zaditor 0.025% (brand)	$2.05044	5 mL	$10.25
Cromolyn 4% eye drops (generic)	$0.59134	10 mL	$5.91

The generic 0.7% NADAC line first appears in the 2026 file on 21 October 2026, so its price may still move. Per mL, the 0.2% strength costs more than twice the 0.1% strength, but a 2.5 mL bottle of once daily drops and a 5 mL bottle of twice daily drops so twice daily 0.1% and once daily 0.2% come out close per day of use.

Our Olopat and Cromal Forte listings

We list two allergy eye drops. Both are Indian products: Olopat is made in India by Ajanta Pharma and Cromal Forte by Cipla. They are not the US OTC Pataday products, they do not carry US Drug Facts labels, and they have not been reviewed by the FDA.

Product	Active ingredient	Maker	Bottle	Pack	Price	Per bottle
Olopat Eye Drop	Olopatadine	Ajanta Pharma	5 mL	3 bottles	$25.00	$8.33
Olopat Eye Drop	Olopatadine	Ajanta Pharma	5 mL	6 bottles	$48.00	$8.00
Olopat Eye Drop	Olopatadine	Ajanta Pharma	5 mL	12 bottles	$93.00	$7.75
Cromal Forte Eye Drop	Sodium cromoglycate (cromolyn)	Cipla	5 mL	1 bottle	$7.00	$7.00
Cromal Forte Eye Drop	Sodium cromoglycate (cromolyn)	Cipla	5 mL	3 bottles	$16.00	$5.33
Cromal Forte Eye Drop	Sodium cromoglycate (cromolyn)	Cipla	5 mL	6 bottles	$29.00	$4.83

Prices are from our product listings as of 5 November 2026, before shipping. Our listing does not state the Olopat strength. An Indian pharmacy listing (Truemeds) shows an Ajanta product named "Olopat Bak Free Eye Drops 5Ml," listed as olopatadine hydrochloride 0.1% and free of the preservative benzalkonium chloride, and our listing gives twice daily directions, which match the 0.1% strength. We could not confirm from Ajanta which version we supply. Check the strength printed on the bottle and follow the directions for that strength. The preservative may differ from the US products, so read the carton before following the US contact lens advice above. The Cromal Forte strength is also not stated on our listing; check the bottle.

Our shipping page lists standard registered shipping at a $25 flat rate, free on orders of $149 or more, with 7 to 14 business days to the US. The smallest Olopat order therefore costs $50.00 delivered, while a US pharmacy pays about $6.20 for a generic 0.1% bottle that you can buy without a prescription today. For most US readers a local OTC bottle is faster and cheaper. Our listings make more sense where olopatadine is not sold over the counter or costs more.

Importing eye drops into the US

The FDA's personal importation page says: "In most circumstances, it is illegal for individuals to import drugs or devices into the U.S. for personal use" and "If a drug is approved for use in another country but is an unapproved new drug in the U.S. it is illegal to import." The same page describes limited situations in which FDA personnel may consider a more permissive decision. Check your own situation before ordering. Our guide to eye drop recalls and checking your bottle explains what to look at when a bottle arrives.

Looking after the bottle

• Do not touch the tip to the eye, lashes, fingers or any surface; recap after each use.
• Do not use the drops if the solution changes color or becomes cloudy.
• Use your own bottle; do not share eye drops.
• Wait at least 5 minutes between olopatadine and any other eye drop.
• Keep out of reach of children.

Sources

• Pataday Twice Daily Relief (olopatadine 0.1%) Drug Facts, Alcon, DailyMed setid b7a24375-25df-4405-aa7c-34c46af51194, January 2026. DailyMed
• Pataday Once Daily Relief (olopatadine 0.2%) Drug Facts, Alcon, DailyMed setid 1c7d2342-ba1c-4244-9814-d92a05725d4e, January 2026. DailyMed
• Pataday Once Daily Relief Extra Strength (olopatadine 0.7%) Drug Facts, Alcon, DailyMed setid 6d07a5d6-265c-4735-97b3-8a2575b276cb, January 2026. DailyMed
• Olopatadine hydrochloride ophthalmic solution USP 0.1%, Alembic, prescription label revised 12/2018, DailyMed setid 7b36e554-d68a-47e0-bf3c-f4cfdc3746b6. DailyMed
• Olopatadine hydrochloride ophthalmic solution USP 0.2%, Alembic, prescription label, DailyMed setid dbcdf10c-5adb-4d48-97ce-f4b82c6bc77d. DailyMed
• PAZEO (olopatadine hydrochloride ophthalmic solution) 0.7% prescribing information, Alcon, revised January 2015, Drugs@FDA. FDA label PDF
• FDA supplement approval letter, NDA 206276/S-005 (prescription to OTC switch of olopatadine 0.7%), signed 13 July 2020. FDA letter PDF
• FDA statement, "FDA Approves Three Drugs for Nonprescription Use Through Rx-to-OTC Switch Process," 14 February 2020. PR Newswire copy
• Drugs@FDA application records for NDA 020688, 021545 and 206276, via openFDA. openFDA
• Zaditor (ketotifen 0.025%) Drug Facts, Alcon, DailyMed setid ac66b1e4-c2b0-a4c3-09e3-ebd44a2f7c9f. DailyMed
• Cromolyn sodium ophthalmic solution USP 4%, Sandoz, DailyMed setid b32851c3-cd97-4be4-a09c-1deab1d6966b, February 2025. DailyMed
• Torkildsen G et al. Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model. Clin Ophthalmol 2015. PubMed 26392751.
• McLaurin E et al. Phase 3 randomized double-masked study of efficacy and safety of once-daily 0.77% olopatadine hydrochloride ophthalmic solution. Cornea 2015. PubMed 26266427.
• McLaurin E et al. Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77%. Clin Ophthalmol 2017. PubMed 28652694.
• Patel D et al. Topical olopatadine hydrochloride versus ketotifen fumarate for allergic conjunctivitis. J Ophthalmic Vis Res 2018. PubMed 29719638.
• Mortemousque B et al. Comparison of preservative-free ketotifen fumarate and preserved olopatadine hydrochloride eye drops. J Fr Ophtalmol 2014. PubMed 24388379.
• Li J et al. Comparison of olopatadine with ketotifen for allergic conjunctivitis: a meta-analysis. Postepy Dermatol Alergol 2023. PubMed 37312902.
• Kam KW et al. Topical olopatadine in the treatment of allergic conjunctivitis: a systematic review and meta-analysis. Ocul Immunol Inflamm 2017. PubMed 27192186.
• Dr. Reddy's Laboratories, launch of OTC olopatadine hydrochloride ophthalmic solution USP 0.7%, 14 January 2026 (SEC filing exhibit 99.1).
• CMS National Average Drug Acquisition Cost (NADAC), 2026 dataset, latest week 4 November 2026. data.medicaid.gov
• FDA, Personal Importation. fda.gov